Modality
Degrader
MOA
PCSK9i
Target
KIF18A
Pathway
Sphingolipid
IPFMGLN
Development Pipeline
Preclinical
~Oct 2016
→ ~Jan 2018
Phase 1
Apr 2018
→ Aug 2025
Phase 1Current
NCT06896211
449 pts·LN
2024-03→TBD·Active
NCT04730786
283 pts·IPF
2018-04→2025-08·Completed
732 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-08-138mo agoInterim· IPF
Trial Timeline
Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q4
P1
Complet…
P1
Active
Catalysts
Interim
2025-08-13 · 8mo ago
IPF
ActiveCompleted|StartCompletionToday
Trials (2)
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Niranesiran | Johnson & Johnson | Phase 2 | KIF18A | |
| MRK-8368 | Merck & Co | Phase 3 | ALK | |
| Ribofutibatinib | AstraZeneca | Phase 2/3 | SOS1 | |
| AZN-4015 | AstraZeneca | Preclinical | BCMA | |
| Polazasiran | Amgen | Phase 2 | LAG-3 | |
| Cevitinib | Regeneron | Phase 3 | FGFR | |
| Riluinavolisib | Moderna | NDA/BLA | KIF18A | |
| INC-1261 | Incyte | Phase 1/2 | PRMT5 | |
| Mavutuximab | Hansoh Pharma | Phase 2/3 | PI3Kα | |
| NUV-2032 | Nuvalent | Preclinical | KIF18A |